Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACXPNASDAQ:FWPOTCMKTS:LTUSNASDAQ:VCNXNASDAQ:VRPX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$2.02-0.5%$2.43$1.17▼$8.82$31.84M-1.9156,858 shs85,169 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/ALTUSLotus Pharmaceuticals$0.01$0.01$0.00▼$0.01$13.47M-0.4216,357 shs39,766 shsVCNXVaccinex$5.93+18.6%$7.43$4.43▼$100.80$6.16M0.7411,528 shs8,465 shsVRPXVirpax Pharmaceuticals$2.87-9.5%$3.70$2.40▼$11.77$3.36M1.3820,382 shs8,337 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-0.49%-5.16%-2.88%-47.80%-32.89%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%LTUSLotus Pharmaceuticals0.00%-28.57%0.00%+17.65%-54.55%VCNXVaccinex+18.50%+23.56%-22.37%-34.72%-91.96%VRPXVirpax Pharmaceuticals-7.12%-26.60%-26.03%-7.72%-57.00%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars).MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACXPAcurx Pharmaceuticals1.0451 of 5 stars3.52.00.00.00.61.70.0FWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AVCNXVaccinex0.2851 of 5 stars0.03.00.00.00.04.20.0VRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals3.00Buy$12.00494.06% UpsideFWPForward Pharma A/SN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest ACXP, LTUS, VRPX, FWP, and VCNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2024ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $12.002/28/2024ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.34 per shareN/AFWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AVCNXVaccinex$570K12.82N/AN/A($2.59) per share-2.29VRPXVirpax PharmaceuticalsN/AN/AN/AN/A$1.65 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.58M-$1.15N/AN/AN/AN/A-289.69%-185.19%5/15/2024 (Confirmed)FWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/AVCNXVaccinex-$20.25M-$100.86N/A∞N/AN/A-2,667.31%-571.70%5/20/2024 (Estimated)VRPXVirpax Pharmaceuticals-$15.19M-$11.70N/A∞N/AN/A-169.04%-106.39%5/10/2024 (Estimated)Latest ACXP, LTUS, VRPX, FWP, and VCNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024N/AACXPAcurx Pharmaceuticals-$0.24N/A+$0.24N/AN/AN/A 4/2/2024Q4 2023VCNXVaccinexN/A-$39.40-$39.40-$39.40N/AN/A3/15/2024Q4 2023ACXPAcurx Pharmaceuticals-$0.26-$0.38-$0.12-$0.38N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AVCNXVaccinexN/AN/AN/AN/AN/AVRPXVirpax PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A2.532.53FWPForward Pharma A/SN/A18.43N/ALTUSLotus PharmaceuticalsN/AN/AN/AVCNXVaccinexN/A0.570.57VRPXVirpax PharmaceuticalsN/A1.251.25OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%FWPForward Pharma A/S12.57%LTUSLotus PharmaceuticalsN/AVCNXVaccinex50.11%VRPXVirpax Pharmaceuticals32.23%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals35.30%FWPForward Pharma A/S71.47%LTUSLotus PharmaceuticalsN/AVCNXVaccinex51.50%VRPXVirpax Pharmaceuticals6.23%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals415.76 million10.20 millionOptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableLTUSLotus Pharmaceuticals2332.69 billionN/ANot OptionableVCNXVaccinex381.23 million598,000No DataVRPXVirpax Pharmaceuticals71.17 million1.10 millionNot OptionableACXP, LTUS, VRPX, FWP, and VCNX HeadlinesSourceHeadlineVRPX Stock Earnings: Virpax Pharmaceuticals Misses EPS for Q4 2023investorplace.com - April 24 at 3:06 PMVirpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutionsmsn.com - April 2 at 11:02 AMVirpax Pharmaceuticals Reports 2023 Year-End Resultsbusinesswire.com - March 26 at 7:30 AMVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Pricefinance.yahoo.com - February 27 at 10:21 AMVirpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Pricebusinesswire.com - February 27 at 7:31 AMVirpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.businesswire.com - February 27 at 7:30 AMVirpax Pharmaceuticals Reports Promising Results in Probudur Pilot Studymsn.com - February 12 at 7:33 AMAnalysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)markets.businessinsider.com - February 9 at 7:40 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)markets.businessinsider.com - February 7 at 3:59 PMVirpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Researchpharmiweb.com - February 7 at 10:56 AMVirpax Pharmaceuticals Inc (VRPX)investing.com - January 23 at 1:47 PMVirpax Pharmaceuticals shareholders okay reverse stock splitmsn.com - December 29 at 7:54 PMTitan Pharmaceuticals to conduct 1-for-20 reverse stock splitmsn.com - December 28 at 6:06 PMVRPX Virpax Pharmaceuticals, Inc.seekingalpha.com - November 22 at 3:08 PMPromising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax Pharmaceuticalsmarkets.businessinsider.com - November 18 at 12:51 AMVirpax Pharmaceuticals gets non-compliance notice from Nasdaqmsn.com - November 17 at 9:20 AMVirpax Pharmaceuticals CEO and Chairman resigns on ongoing litigationmsn.com - November 17 at 9:20 AMVirpax Pharmaceuticals Announces Leadership Transitionfinance.yahoo.com - November 17 at 9:20 AMVirpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filingfinance.yahoo.com - November 17 at 9:20 AMVirpax Pharmaceuticals GAAP EPS of -$0.51msn.com - November 15 at 7:29 PMVirpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Reviewfinance.yahoo.com - October 31 at 10:01 AMAnalysts Are Bullish on These Healthcare Stocks: Virpax Pharmaceuticals (VRPX), Kura Oncology (KURA)markets.businessinsider.com - September 28 at 4:00 PMVirpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studiesfinance.yahoo.com - September 27 at 1:53 PMVirpax Pharmaceuticals to Present at the LD Micro Main Event XVIfinance.yahoo.com - September 26 at 2:19 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcurx PharmaceuticalsNASDAQ:ACXPAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Forward Pharma A/SNASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.Lotus PharmaceuticalsOTCMKTS:LTUSLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.VaccinexNASDAQ:VCNXVaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.Virpax PharmaceuticalsNASDAQ:VRPXVirpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.